Table 1.
Main characteristic of the eligible studies in the meta-analysis
| Study name/ Author | Year | Study Phase/design | Numbers of parents | Male (%) | Median age | Arm | Median OS | HR (95%CI) | Median PFS | HR (95%CI) | HBV + (%) | Asia (%) | Type of study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMbrave150 Finn et al. [22] | 2020 | III/RCT | 336 | 277(82%) | 64 | Atezolizumab + Bevacizumab | - | 0.58 (0.42–0.79) | 6.8 | 0.59 (0.47–0.76) | 164(49%) | 133 (40%) | Full text |
| 165 | 137(83%) | 66 | Sorafenib | 13.2 | 4.3 | 76(46%) | 68 (41%) | ||||||
| ORIENT-32 Ren et al. [23] | 2021 | III/RCT | 380 | 334(88%) | 53 | Sintilimab + Bevacizumab | - | 0.57 (0.43–0.75) | 4.6 | 0.56 (0.46–0.70) | 359(94%) | 380 (100%) | Full text |
| 191 | 171(90%) | 54 | Sorafenib | 10.4 | 2.8 | 179(94%) | 191 (100%) | ||||||
| COSMIC-312 Kelley et al. [24] | 2022 | III/RCT | 432 | 360(83) | 64 | Atezolizumab + Cabozantinib | 15.4 | 0.90 (0.69–1.18) | 6.8 | 0.63 (0.44–0.91) | 127(29%) | 120(28%) | Full text |
| 217 | 186(86) | 64 | Sorafenib | 15.5 | 4.2 | 64(29%) | 63(29%) | ||||||
| Leap-002 Finn et al. [25] | 2022 | III/RCT | 395 | 317(80.3%) | 66 | Pembrolizumab + Lenvatinib | 21.2 | 0.840(0.71–1.0) | 8.2 | 0.834 (0.71–0.98) | 192(48.6%) | 121(30.6%) | Absctrct |
| 399 | 327(82%) | 66 | Lenvatinib | 19.0 | 8.1 | 193(48.4%) | 123(30.8%) | ||||||
| SHR-1210-III-310 Qin et al. [26] | 2022 | III/RCT | 271 | 227(83.5%) | 58 | Camrelizumab + Apatinib | 22.1 | 0.62 (0.49–0.80) | 5.6 | 0.52 (0.41–0.65) | 208(76.8%) | 225(83.0%) | Absctrct |
| 271 | 230(84.9%) | 56 | Sorafenib | 15.2 | 3.7 | 197(72.7%) | 224(82.7%) |